De novo or transformed indolent B-cell lymphoma
Showing 1 - 25 of >10,000
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +11 more
- Biopsy
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)
Active, not recruiting
- Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
-
Los Angeles, California
- +6 more
Dec 1, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
-
Duarte, California
- +2 more
Mar 9, 2022
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Ruijin Hospital
Dec 1, 2022
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)
Completed
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Imprime PGG
- Rituximab
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 20, 2022
Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- +8 more
- Biospecimen Collection
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 8, 2023
Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +9 more
-
Duarte, California
- +3 more
Nov 17, 2022
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial
Not yet recruiting
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +2 more
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 5, 2023
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,
Recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Zilovertamab vedotin
- Nemtabrutinib
-
Spokane, Washington
- +1 more
Aug 12, 2022
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic
Not yet recruiting
- Recurrent Transformed Chronic Lymphocytic Leukemia
- +7 more
- Biospecimen Collection
- +9 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 15, 2023
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)
Recruiting
- B Cell Lymphoma
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Severe COVID-19 Infection in CLL or B-NHL Who Received
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- (no location specified)
Apr 6, 2023
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +8 more
- Cyclophosphamide
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 30, 2022
Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)
Recruiting
- Lymphoma, B-Cell
- Rituximab Biosimilar
- Pegylated Interferon α-2b
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023